Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

MediciNova Inc

MNOV ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.31

▲ +0.00%

Market Cap $64.48M · Vol 15.40K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$64.48M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

-8.33%

YoY

RSI (14)

48.15

Momentum

Beta

0.61

vs Market

52W High

$1.96

33.16% below

52W Low

$1.17

11.97% above

Volume

15.40K

Avg 10.21K

P/B

1.55

Price-to-book

ROE

N/A

Return on equity

Free Float

97.13%

Public shares

Shariah Compliance8 STANDARDS

✗ MediciNova Inc (MNOV) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MNOV pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.24%

-4.38%

-6.43%

-11.49%

YTD

+0.00%

+0.77%

-43.04%

-62.68%

Financials & Valuation

TTM · Annual

Total Revenue	$409.66K
Net Income	$-11,997,960.00
Revenue Growth (YoY)	+240.60%
Gross Margin	7.58%
Operating Margin	-3,242.47%
Net Profit Margin	-2,928.78%
ROE	N/A
ROA · ROIC	-23.63% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	156.89
P/B	1.55
P/FCF	N/A
EPS Growth	-8.33%
Outstanding Shares	49.22M

Technical Indicators

50-Day SMA	$1.33
200-Day SMA	$1.43
RSI (14)	48.15
Beta	0.61
52-Week High	$1.96
52-Week Low	$1.17

Volume Today	15.40K
Avg Daily Volume (30D)	10.21K
Relative Volume	1.51x
Volatility (10D)	23.71
Volatility (30D)	28.52
Free Float	97.13%

Analyst Consensus

BUY

Current Price $1.31

Mean Target $9.00

52W Low$1.17 52W High$1.96

Current

Target

$1.17 $1.96

Current Analyst target

+587.02% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SNG8P4

ISINUS58468P2065

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.